SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

HCA Inc./DE – ‘FWP’ on 2/20/24 re: HCA Inc./DE

On:  Tuesday, 2/20/24, at 8:23pm ET   ·   As of:  2/21/24   ·   Accession #:  1193125-24-40337   ·   File #:  333-271537-01

Previous ‘FWP’:  ‘FWP’ on 5/1/23   ·   Latest ‘FWP’:  This Filing

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/21/24  HCA Inc./DE                       FWP                    1:49K  HCA Inc./DE                       Donnelley … Solutions/FA

Prospectus – Free Writing   —   Rule 163 / 433

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: FWP         Prospectus - Free Writing                           HTML     47K 


This is an HTML Document rendered as filed.  [ Alternative Formats ]



  FWP  

Filed pursuant to Rule 433

Issuer Free Writing Prospectus, dated February 20, 2024

Supplementing the Preliminary Prospectus Supplement, dated February 20, 2024

Registration No. 333-271537

HCA Inc.

$1,000,000,000 5.450% Senior Notes due 2031 (the “2031 notes”)

$1,300,000,000 5.600% Senior Notes due 2034 (the “2034 notes”)

$1,500,000,000 6.000% Senior Notes due 2054 (the “2054 notes”)

$700,000,000 6.100% Senior Notes due 2064 (the “2064 notes”)

(collectively, the “notes”)

Pricing Supplement

Pricing Supplement dated February 20, 2024 to HCA Inc.’s Preliminary Prospectus Supplement dated February 20, 2024. This Pricing Supplement is qualified in its entirety by reference to the Preliminary Prospectus Supplement. The information in this Pricing Supplement supplements the Preliminary Prospectus Supplement and supersedes the information in the Preliminary Prospectus Supplement to the extent it is inconsistent with the information in the Preliminary Prospectus Supplement. Financial information presented in the Preliminary Prospectus Supplement is deemed to have changed to the extent affected by changes described herein. Capitalized terms used in this Pricing Supplement but not defined have the meanings given them in the Preliminary Prospectus Supplement.

 

Terms Applicable to the 2031 notes
Issuer    HCA Inc.
Aggregate Principal Amount    $1,000,000,000
Title of Security    5.450% Senior Notes due 2031
Maturity Date    April 1, 2031
Spread to Treasury    120 basis points
Benchmark Treasury    UST 4.000% due January 31, 2031
Benchmark Treasury Price & Yield    98-11+ / 4.275%
Coupon    5.450%
Public Offering Price    99.845% plus accrued interest, if any, from February 23, 2024
Yield to Maturity    5.475%


Interest Payment Dates    April 1 and October 1 of each year, beginning on October 1, 2024
Record Dates    March 15 and September 15 of each year

Net Proceeds to Issuer before

Expenses

   $992,200,000
CUSIP/ISIN Numbers   

CUSIP: 404119 CT4

ISIN: US404119CT49

Optional Redemption   

Prior to February 1, 2031, the 2031 notes will be redeemable, at our option, at any time in whole or from time to time in part, at a redemption, or “make-whole,” price equal to the greater of:

 

(i) 100% of the aggregate principal amount of the 2031 notes to be redeemed, and

 

(ii)  an amount equal to the sum of the present value of (a) the payment on February 1, 2031 of principal of the 2031 notes to be redeemed and (b) the payment of the remaining scheduled payments through February 1, 2031 of interest on the 2031 notes to be redeemed (excluding accrued and unpaid interest to the redemption date and subject to the right of Holders on the relevant record date to receive interest due on the relevant interest payment date) discounted from their scheduled date of payment to the redemption date on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) using a discount rate equal to the Treasury Rate plus 20 basis points

 

plus, in each of clauses (i) and (ii) above, accrued and unpaid interest, if any, to such redemption date.

 

On and after February 1, 2031, the 2031 notes will be redeemable, at our option, at any time in whole or from time to time in part, at a redemption price equal to 100% of the principal amount of such 2031 notes plus accrued and unpaid interest, if any, to such redemption date.

 

Terms Applicable to the 2034 notes
Issuer    HCA Inc.
Aggregate Principal Amount    $1,300,000,000
Title of Security    5.600% Senior Notes due 2034
Maturity Date    April 1, 2034
Spread to Treasury    135 basis points
Benchmark Treasury    UST 4.000% due February 15, 2034

 

-2-


Benchmark Treasury Price & Yield    97-26+ / 4.269%
Coupon    5.600%
Public Offering Price    99.845% plus accrued interest, if any, from February 23, 2024
Yield to Maturity    5.619%
Interest Payment Dates    April 1 and October 1 of each year, beginning on October 1, 2024
Record Dates    March 15 and September 15 of each year

Net Proceeds to Issuer before

Expenses

   $1,289,535,000
CUSIP/ISIN Numbers   

CUSIP: 404119 CU1

ISIN: US404119CU12

Optional Redemption   

Prior to January 1, 2034, the 2034 notes will be redeemable, at our option, at any time in whole or from time to time in part, at a redemption, or “make-whole,” price equal to the greater of:

 

(i) 100% of the aggregate principal amount of the 2034 notes to be redeemed, and

 

(ii)  an amount equal to the sum of the present value of (a) the payment on January 1, 2034 of principal of the 2034 notes to be redeemed and (b) the payment of the remaining scheduled payments through January 1, 2034 of interest on the 2034 notes to be redeemed (excluding accrued and unpaid interest to the redemption date and subject to the right of Holders on the relevant record date to receive interest due on the relevant interest payment date) discounted from their scheduled date of payment to the redemption date on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) using a discount rate equal to the Treasury Rate plus 25 basis points

 

plus, in each of clauses (i) and (ii) above, accrued and unpaid interest, if any, to such redemption date.

 

On and after January 1, 2034, the 2034 notes will be redeemable, at our option, at any time in whole or from time to time in part, at a redemption price equal to 100% of the principal amount of such 2034 notes plus accrued and unpaid interest, if any, to such redemption date.

 

-3-


Terms Applicable to the 2054 notes
Issuer    HCA Inc.
Aggregate Principal Amount    $1,500,000,000
Title of Security    6.000% Senior Notes due 2054
Maturity Date    April 1, 2054
Spread to Treasury    160 basis points
Benchmark Treasury    UST 4.750% due November 15, 2053
Benchmark Treasury Price & Yield    105-02 / 4.441%
Coupon    6.000%
Public Offering Price    99.423% plus accrued interest, if any, from February 23, 2024
Yield to Maturity    6.041%
Interest Payment Dates    April 1 and October 1 of each year, beginning on October 1, 2024
Record Dates    March 15 and September 15 of each year

Net Proceeds to Issuer before

Expenses

   $1,478,220,000
CUSIP/ISIN Numbers   

CUSIP: 404119 CV9

ISIN: US404119CV94

Optional Redemption   

Prior to October 1, 2053, the 2054 notes will be redeemable, at our option, at any time in whole or from time to time in part, at a redemption, or “make-whole,” price equal to the greater of:

 

(i) 100% of the aggregate principal amount of the 2054 notes to be redeemed, and

 

(ii)  an amount equal to the sum of the present value of (a) the payment on October 1, 2053 of principal of the 2054 notes to be redeemed and (b) the payment of the remaining scheduled payments through October 1, 2053 of interest on the 2054 notes to be redeemed (excluding accrued and unpaid interest to the redemption date and subject to the right of Holders on the relevant record date to receive interest due on the relevant interest payment date) discounted from their scheduled date of payment to the redemption date on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) using a discount rate equal to the Treasury Rate plus 25 basis points

 

plus, in each of clauses (i) and (ii) above, accrued and unpaid interest, if any, to such redemption date.

 

On and after October 1, 2053, the 2054 notes will be redeemable, at our option, at any time in whole or from time to time in part, at a redemption price equal to 100% of the principal amount of such 2054 notes plus accrued and unpaid interest, if any, to such redemption date.

 

-4-


Terms Applicable to the 2064 notes
Issuer    HCA Inc.
Aggregate Principal Amount    $700,000,000
Title of Security    6.100% Senior Notes due 2064
Maturity Date    April 1, 2064
Spread to Treasury    170 basis points
Benchmark Treasury    UST 4.750% due November 15, 2053
Benchmark Treasury Price & Yield    105-02 / 4.441%
Coupon    6.100%
Public Offering Price    99.380% plus accrued interest, if any, from February 23, 2024
Yield to Maturity    6.141%
Interest Payment Dates    April 1 and October 1 of each year, beginning on October 1, 2024
Record Dates    March 15 and September 15 of each year

Net Proceeds to Issuer before

Expenses

   $689,535,000
CUSIP/ISIN Numbers   

CUSIP: 404119 CW7

ISIN: US404119CW77

Optional Redemption   

Prior to October 1, 2063, the 2064 notes will be redeemable, at our option, at any time in whole or from time to time in part, at a redemption, or “make-whole,” price equal to the greater of:

 

(i) 100% of the aggregate principal amount of the 2064 notes to be redeemed, and

 

(ii)  an amount equal to the sum of the present value of (a) the payment on October 1, 2063 of principal of the 2064 notes to be redeemed and (b) the payment of the remaining scheduled payments through October 1, 2063 of interest on the 2064 notes to be redeemed (excluding accrued and unpaid interest to the redemption date and subject to the right of Holders on the relevant record date to receive interest due on the relevant interest payment date) discounted from their scheduled date of payment to the redemption date on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) using a discount rate equal to the Treasury Rate plus 30 basis points

 

plus, in each of clauses (i) and (ii) above, accrued and unpaid interest, if any, to such redemption date.

   On and after October 1, 2063, the 2064 notes will be redeemable, at our option, at any time in whole or from time to time in part, at a redemption price equal to 100% of the principal amount of such 2064 notes plus accrued and unpaid interest, if any, to such redemption date.

 

-5-


Terms Applicable to the notes
Change of Control    Upon a Change of Control Triggering Event, each Holder may require the Issuer to repurchase at 101%, plus accrued and unpaid interest, if any.
Trade Date    February 20, 2024
Use of Proceeds   

We estimate that our net proceeds from this offering, after deducting underwriting discounts and estimated offering expenses, will be approximately $4,441,602,500.

 

We intend to use the net proceeds from this offering for the repayment of near-term maturities and for general corporate purposes. Prior to such repayment, we may temporarily repay borrowings outstanding under our senior secured asset-based revolving credit facility.

Denominations    $2,000 and integral multiples of $1,000
Form of Offering    SEC Registered (Registration No. 333-271537)
Joint Book-Running Managers   

BofA Securities, Inc.

Barclays Capital Inc.

Citigroup Global Markets Inc.

J.P. Morgan Securities LLC

Capital One Securities, Inc.

Goldman Sachs & Co. LLC

Mizuho Securities USA LLC

Morgan Stanley & Co. LLC

RBC Capital Markets, LLC

SMBC Nikko Securities America, Inc.

Truist Securities, Inc.

Wells Fargo Securities, LLC

Co-Managers   

Credit Agricole Securities (USA) Inc.

Fifth Third Securities, Inc.

PNC Capital Markets LLC

Scotia Capital (USA) Inc.

BNP Paribas Securities Corp.

CIBC World Markets Corp.

DNB Markets, Inc.

Regions Securities LLC

 

-6-


Settlement Date   

February 23, 2024 (T+3)

 

We expect that delivery of the notes will be made to investors on or about February 23, 2024, which will be the third business day following the date of this pricing term sheet (such settlement being referred to as “T+3”). Under Rule 15c6-1 under the Exchange Act, trades in the secondary market are required to settle in two business days, unless the parties to any such trade expressly agree otherwise. Accordingly, purchasers who wish to trade notes prior to the delivery of the notes hereunder will be required, by virtue of the fact that the notes initially settle in T+3, to specify an alternate settlement arrangement at the time of any such trade to prevent a failed settlement. Purchasers of the notes who wish to trade the notes prior to their date of delivery hereunder should consult their advisors.

 

 

The Issuer has filed a registration statement (including a prospectus and a related preliminary prospectus supplement) with the United States Securities and Exchange Commission (“SEC”) for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement, the preliminary prospectus supplement and other documents HCA Healthcare, Inc. has filed with the SEC for more complete information about the Issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, copies of the preliminary prospectus supplement and accompanying prospectus may be obtained from BofA Securities, Inc., NC1-022-02-25, 201 North Tryon Street, Charlotte, NC 28255-0001, Attn: Prospectus Department, by telephone 1-800-294-1322 or by emailing: dg.prospectus_requests@bofa.com; Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, barclaysprospectus@broadridge.com or by telephone at 1-888-603-5847; Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone: 1-800-831-9146 or by emailing: prospectus@citi.com; or J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone: 1-866-803-9204.

This communication should be read in conjunction with the preliminary prospectus supplement and the accompanying prospectus. The information in this communication supersedes the information in the preliminary prospectus supplement and the accompanying prospectus to the extent inconsistent with the information in such preliminary prospectus supplement and the accompanying prospectus.

ANY DISCLAIMERS OR OTHER NOTICES THAT MAY APPEAR BELOW ARE NOT APPLICABLE TO THIS COMMUNICATION AND SHOULD BE DISREGARDED. SUCH DISCLAIMERS OR OTHER NOTICES WERE AUTOMATICALLY GENERATED AS A RESULT OF THIS COMMUNICATION BEING SENT VIA BLOOMBERG OR ANOTHER EMAIL SYSTEM.

 

-7-


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘FWP’ Filing    Date    Other Filings
4/1/34
2/15/34
1/1/34
4/1/31
2/1/31
1/31/31
10/1/24
2/23/24
Filed as of:2/21/24
Filed on:2/20/24424B3
 List all Filings 
Top
Filing Submission 0001193125-24-040337   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Mon., Apr. 29, 11:46:30.1am ET